Cefotaxime use in pediatric infections

Area of Science:

• Pediatric Infectious Diseases
• Antimicrobial Stewardship

Background:

• Cefotaxime has been a cornerstone in treating serious pediatric bacterial infections, including meningitis and sepsis, for over a decade in the US.
• While effective against many pathogens, the emergence of penicillin- and cephalosporin-resistant pneumococci presents a growing clinical challenge.
• Overuse of cephalosporins has led to increased antimicrobial resistance and resource strain in healthcare settings.

Purpose of the Study:

• To review the established role of cefotaxime in pediatric infectious disease management.
• To highlight the evolving landscape of pediatric bacterial pathogens and resistance patterns.
• To emphasize the importance of antimicrobial stewardship for cephalosporin use in pediatric populations.

Main Methods:

• Review of clinical literature and usage patterns of cefotaxime in pediatric centers.
• Analysis of common pediatric bacterial infections and their causative agents.
• Examination of antimicrobial resistance trends, particularly for Streptococcus pneumoniae.

Main Results:

• Cefotaxime remains a critical therapeutic option for severe pediatric infections, despite reduced Haemophilus influenzae type b incidence.
• Increasing resistance to penicillin and third-generation cephalosporins among pneumococci necessitates careful treatment strategies.
• Widespread and sometimes inappropriate use of cephalosporins has contributed to resistance and increased healthcare costs.

Conclusions:

• Cefotaxime continues to be essential for treating serious pediatric bacterial infections.
• The rise of resistant pneumococci underscores the need for updated treatment guidelines and vigilant monitoring.
• Judicious prescribing of cefotaxime and other cephalosporins is paramount to preserve their efficacy and manage healthcare resources effectively.